Top Tweets for #serds
💡 Another 🔝 @OncoAlert HORIZONS session exploring one of the🔑 challenges in HR+/HER2− advanced #BreastCancer : how to navigate treatment after progression on CDK4/6 + ET ❓
From resistance mechanisms to #SERDs and biomarker-driven strategies - well worth watching ⬇️⬇️⬇️
The OncoAlert HORIZONS Series: Breast Cancer
What happens when Watch & Wait fails?
How Mechanism based therapies are rewriting Cancer Care
WATCH THE ENTIRE VIDEO HERE👉 https://t.co/V0wFci9MP8
In this session, we explore: Therapeutic options after CDK4/6 inhibitor + endocrine therapy in HR+, HER2– advanced/metastatic #BreastCancer , and the emerging role of SERD-based combination strategies in this setting.
👩⚕️ Faculty: Dr. Sherene Loi
@LoiSher Peter MacCallum Cancer Centre, Australia 🇦🇺 Dr. Elisa Agostinetto @ElisaAgostinett
Institut Jules Bordet, Belgium 🇧🇪
The post-CDK4/6 inhibitor landscape in HR+/HER2– advanced breast cancer represents one of the most pressing unmet needs in oncology. While CDK4/6 inhibitors combined with endocrine therapy have firmly established themselves as the frontline standard, disease progression on this backbone remains nearly universal, driven by heterogeneous resistance mechanisms including ESR1 mutations, PI3K/AKT/mTOR pathway alterations, and RB1 loss.
This biological diversity highlights the limitations of one-size-fits-all approaches. Next-generation oral selective estrogen receptor degraders (SERDs)—such as elacestrant, camizestrant, and imlunestrant—are reshaping the field.
These agents achieve more complete estrogen receptor degradation than fulvestrant, show activity in ESR1-mutant disease, and are being actively evaluated in combination strategies with CDK4/6 and targeted therapies.
Together, they are helping shift the post-CDK4/6 setting toward a more dynamic, biomarker-informed treatment paradigm.
This OncoAlert Horizons educational series was supported by an unrestricted educational grant from Roche.
All content was independently developed and fully controlled by the faculty.
OncoAlert Horizons faculty:
@LoiSher
@JavierCortesMD
@BarbaraPistill2
@BianchiniGP
@ElisaAgostinett
Sybille Loibl
Rupert Barsch
François-Clément Bidard
Cristina Saura
Pinging our #BreastCancer Faculty
@matteolambe
@aftimosp
@E_de_Azambuja
@DrSGraff
@ErikaHamilton9
@double_whammied
@maryam_lustberg
@raalbany
@hoperugo
@stolaney1
@LoiSher
@SirohiBhawna
@jamecancerdoc
@JavierCortesMD
@JaniceTNBCmets
@Prof_Nadia_H
@nataliagandur
@acampsmalea
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@realbowtiedoc
@Lucarecco
@GaiaGriguolo
@JankovicK
@MarioBalsaMD
@Onco_Cifu88
In this episode of #BreastCancerBreakthroughs, Dr. Harold Burstein (@DrHBurstein) and Dr. Erica Mayer (@elmayermd) discuss key updates from #ASCO2026 on the #persevERA trial and oral #SERDs for metastatic breast cancer.
https://t.co/zqjWmIJ4Bm
Nancy Lin, MD (@nlinmd), presents on ER+ Metastatic Breast Cancer: #SERDs, #CDK4/6, #PI3K, and novel endocrine agents at the #DanaFarberBreastCancerCourse.
#MBC #BreastCancer
Check out this recent review on oral selective estrogen receptor degraders (#SERDs) for the treatment of hormone receptor-positive, HER2-negative #BreastCancer.
👉https://t.co/3FAC4LCxYr
@ValenzaCarmine @curijoey @darioT_
Check out this recent systematic review and meta-analysis on oral selective estrogen receptor degraders in hormone receptor-positive, HER2-negative advanced #BreastCancer.
https://t.co/KrIHRkwdoS
@PTarantinoMD @FelipeBatalini #SERDs
Antonio Llombart-Cussac highlights the potential of #SERDs in premenopausal #BreastCancer 🌸: improving outcomes, offering tamoxifen alternatives, and optimizing ovarian suppression ⚖️
Watch: https://t.co/oG7KWs0CSz
#bcsm #Oncology
ICYMI: the #BreastCancerBreakthroughs webinar recording is now available! Watch @DanaFarber
physician-scientists share expert perspectives on new data and emerging treatment approaches presented at #SABCS25. They cover:
🔹 Maintenance strategies for HER2+ #MBC
🔹 #SERDs in early and late stage #BreastCancer
🔹 #ADCs in ER+ MBC
🔹 Local therapy and screening
🔹 #ctDNA in clinical studies
Watch here: https://t.co/GIXSg9rvSN
Lindsay Northrop, #BreastCancer survivor and patient advocate @DanaFarber, talks with Dr. Harold Burstein (@DrHBurstein), about how recent advances in breast cancer research presented at #SABCS25 will impact patient care. They also discuss patient advocacy, oral #SERDs, #ADCs and treatment options for #MetastaticBreastCancer. Watch here ⬇️
https://t.co/KlYX1UwbZa
In this #BreastCancerBreakthroughs video Drs. Harold Burstein (@DrHBurstein) and Rinath Jeselsohn (@RMJesel) discuss oral selective estrogen receptor degraders (#SERDs), specifically focusing on the #lidERA, #evERA, and #EMBER3 trials.
https://t.co/ePR2Kom0iA
📽️Our #BreastCancerBreakthroughs webinar recording is now available!
Watch @DanaFarber breast cancer experts discuss important research from #SABCS25 including:
🔹Maintenance strategies for HER2+ #MBC
🔹#SERDs in early and late stage #breastcancer
🔹#ADCs in ER+ #MetastaticBreastCancer
🔹Local therapy and screening
🔹#ctDNA impact on clinical studies
👉https://t.co/N70yFQ8EgF
@DrHBurstein @stolaney1 @nlinmd @EMittendorfMD @drsarahsam #AnaGarridoCastro
Watch as Drs. Harold Burstein (@DrHBurstein) and Erica Mayer (@elmayermd) discuss the #evERA and #SERENA06 trials investigating oral selective estrogen receptor degraders (#SERDs), which were presented at ESM25.
https://t.co/n2SBKWUib1
@GaiaGriguolo @OncoAlert Promising results from the #EvERA trial at #ESMO25 💫
Giredestrant + everolimus significantly improved PFS (9.99 vs 5.45 mo; HR 0.56 ITT) even stronger in ESR1mut pts (HR 0.38) ✅
Toxicity profile as expected. Another win for oral #SERDs in HR+/HER2- #BreastCancer 💊
Need guidance on tx selection/sequencing in ER+ #MBC? Sign up for a podcast-style live virtual #MedEd workshop series on oral #SERDs hosted by @jhaveri_komal. Join us 8/25. Produced with @MBCaware https://t.co/nkEcaQjgX1 #BreastCancer #Oncology
Don’t miss the opportunity to learn about the foundations, evidence, & practicalities of use of oral #SERDs in ER+ #MBC in this virtual #MedEd Part 1 workshop hosted by @jhaveri_komal and expert @professorSteph7 on 8/13 at 12:00 PM EDT! Produced with @MBCaware https://t.co/NTwbotfibP #BCSM
Need guidance on tx selection/sequencing in ER+ #MBC? Sign up for a podcast-style live virtual #MedEd workshop series on oral #SERDs hosted by @jhaveri_komal. Join us 8/13, 8/21, & 8/25. Produced with @MBCaware https://t.co/nkEcaQjgX1 #BreastCancer #Oncology
@TMS190 @mybmcWardHE @MelwynF55275571 @Ashcorruption @dias_reggie @joytrichur @mybmc #AEMaint #SERds
Could remove pucca constructions of embedded stalls,shop's steps,partition walls etc found on public open spaces footpaths, roads etc
However neither own accord nor upon reports initiate actions results into proliferation?
#BMC Passive #Honble_Court Active!
Dr. Erica Mayer (@elmayermd) started off Session VI on #ERpositive breast cancer with a comprehensive review of new treatment approaches in early ER+ #BreastCancer. She discussed adjuvant #CDK 4/6 inhibitors, neoadjuvant IO for HR+ disease, and oral #SERDs.
#HarvardBreastCancerCourse
Last Seen Hashtags on Sotwe
pissdrinker
Seen from Netherlands
somaliwasmo
hidden camera sex
Seen from Turkey
yesilfirin
Seen from United States
snapchat
Seen from Argentina
xlii or #TEENAGER or #momson or #nolimit() +filter:native_video
Seen from Turkey
brosis
Seen from Greece
habeshaporn
ıspartaesc
Seen from Turkey
minichat()()()()()()()()()()()()()()
Seen from Turkey
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.4M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
83.9M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.3M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.3M followers
Bill Gates
@billgates
65.1M followers
Selena Gomez
@selenagomez
63M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers